Is WHWK or AVTX more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -53.89% -49.97% Avalo Therapeutics N/A -58.03% -48.22%

Is WHWK or FTH more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -53.89% -49.97% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Is SANA or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -53.89% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -103.02% -39.16% Whitehawk Therapeutics N/A -53.89% -49.97%

Whitehawk Therapeutics (WHWK) Competitors

$3.82 -0.22 (-5.45%)

Closing price 04:00 PM Eastern

Extended Trading

$3.88 +0.06 (+1.44%)

As of 05:59 PM Eastern

Compare

WHWK vs. LXRX, AVTX, WVE, FTH, and SANA

Should you buy Whitehawk Therapeutics stock or one of its competitors? Whitehawk Therapeutics's main competitors and comparable companies include Lexicon Pharmaceuticals (LXRX), Avalo Therapeutics (AVTX), WAVE Life Sciences (WVE), Sensei Biotherapeutics (FTH), and Sana Biotechnology (SANA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Whitehawk Therapeutics compare to Lexicon Pharmaceuticals?

Whitehawk Therapeutics (NASDAQ:WHWK) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Whitehawk Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Whitehawk Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Whitehawk Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 113.54%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 120.87%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Whitehawk Therapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	30.66	-$20.60M	-$1.12	N/A
Lexicon Pharmaceuticals	$49.80M	18.41	-$50.34M	-$0.15	N/A

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 2 mentions for Lexicon Pharmaceuticals and 0 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.90 beat Lexicon Pharmaceuticals' score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Whitehawk Therapeutics	Very Positive
Lexicon Pharmaceuticals	Neutral

Summary

Whitehawk Therapeutics and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Avalo Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Whitehawk Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Whitehawk Therapeutics has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	30.66	-$20.60M	-$1.12	N/A
Avalo Therapeutics	$60K	13,675.65	-$78.26M	-$4.37	N/A

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Avalo Therapeutics had 5 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 5 mentions for Avalo Therapeutics and 0 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.90 beat Avalo Therapeutics' score of 0.43 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Whitehawk Therapeutics	Very Positive
Avalo Therapeutics	Neutral

Whitehawk Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 113.54%. Avalo Therapeutics has a consensus target price of $45.10, indicating a potential upside of 194.77%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Whitehawk Therapeutics' return on equity of -53.89% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Summary

Whitehawk Therapeutics beats Avalo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to WAVE Life Sciences?

Whitehawk Therapeutics (NASDAQ:WHWK) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Whitehawk Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

Whitehawk Therapeutics presently has a consensus price target of $8.20, indicating a potential upside of 113.54%. WAVE Life Sciences has a consensus price target of $22.31, indicating a potential upside of 463.45%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Whitehawk Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	30.66	-$20.60M	-$1.12	N/A
WAVE Life Sciences	$65.37M	11.94	-$204.38M	-$1.09	N/A

In the previous week, WAVE Life Sciences had 10 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 10 mentions for WAVE Life Sciences and 0 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.90 beat WAVE Life Sciences' score of -0.43 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Whitehawk Therapeutics	Very Positive
WAVE Life Sciences	Neutral

Whitehawk Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.3, indicating that its share price is 230% less volatile than the broader market.

Summary

WAVE Life Sciences beats Whitehawk Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Sensei Biotherapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Whitehawk Therapeutics has higher revenue and earnings than Sensei Biotherapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	30.66	-$20.60M	-$1.12	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

In the previous week, Sensei Biotherapeutics had 6 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for Sensei Biotherapeutics and 0 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.90 beat Sensei Biotherapeutics' score of 0.45 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Whitehawk Therapeutics	Very Positive
Sensei Biotherapeutics	Neutral

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Whitehawk Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 113.54%. Sensei Biotherapeutics has a consensus target price of $56.25, indicating a potential upside of 78.29%. Given Whitehawk Therapeutics' higher probable upside, equities analysts plainly believe Whitehawk Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

Whitehawk Therapeutics' return on equity of -53.89% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-53.89%	-49.97%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Whitehawk Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.28, indicating that its stock price is 128% less volatile than the broader market.

Summary

Whitehawk Therapeutics beats Sensei Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Sana Biotechnology had 4 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 0 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.90 beat Sana Biotechnology's score of 0.42 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sana Biotechnology	Neutral
Whitehawk Therapeutics	Very Positive

Sana Biotechnology currently has a consensus price target of $9.33, suggesting a potential upside of 203.03%. Whitehawk Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 113.54%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sana Biotechnology has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Whitehawk Therapeutics' return on equity of -53.89% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Whitehawk Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Whitehawk Therapeutics	$7.14M	30.66	-$20.60M	-$1.12	N/A

Summary

Sana Biotechnology beats Whitehawk Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WHWK vs. The Competition

Export

Metric	Whitehawk Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$218.92M	$3.90B	$7.20B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	-3.43	13.95	274.58	25.69
Price / Sales	30.66	1,370.96	644.00	85.88
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	1.33	15.30	10.44	6.32
Net Income	-$20.60M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-4.95%	-0.22%	0.51%	1.35%
1 Month Performance	-18.82%	-6.05%	-3.38%	-3.68%
1 Year Performance	100.00%	34.38%	16.04%	5.56%

Whitehawk Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WHWK Whitehawk Therapeutics	3.0045 of 5 stars	$3.82 -5.4%	$8.20 +114.7%	+112.6%	$217.78M	$7.14M	N/A	23	Positive News
LXRX Lexicon Pharmaceuticals	1.4896 of 5 stars	$2.04 +1.0%	$4.55 +123.0%	+87.9%	$898.81M	$49.80M	N/A	81	News Coverage Positive News
AVTX Avalo Therapeutics	3.4382 of 5 stars	$16.69 +0.7%	$45.10 +170.2%	+41.1%	$889.18M	$60K	N/A	33
WVE WAVE Life Sciences	2.5798 of 5 stars	$4.44 -1.6%	$22.31 +402.5%	-36.9%	$887.70M	$42.73M	N/A	317	News Coverage Positive News Analyst Forecast
FTH Sensei Biotherapeutics	4.1363 of 5 stars	$35.13 +2.6%	$56.25 +60.1%	N/A	$884.78M	N/A	N/A	29	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WHWK) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. LXRX, AVTX, WVE, FTH, and SANA

How does Whitehawk Therapeutics compare to Lexicon Pharmaceuticals?

Summary

How does Whitehawk Therapeutics compare to Avalo Therapeutics?

Summary

How does Whitehawk Therapeutics compare to WAVE Life Sciences?

Summary

How does Whitehawk Therapeutics compare to Sensei Biotherapeutics?

Summary

How does Whitehawk Therapeutics compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. LXRX, AVTX, WVE, FTH, and SANA

How does Whitehawk Therapeutics compare to Lexicon Pharmaceuticals?

Which has more volatility & risk, WHWK or LXRX?

Is WHWK or LXRX more profitable?

Do analysts prefer WHWK or LXRX?

Which has preferable earnings and valuation, WHWK or LXRX?

Do insiders and institutionals believe in WHWK or LXRX?

Does the media refer more to WHWK or LXRX?

Summary

How does Whitehawk Therapeutics compare to Avalo Therapeutics?

Which has more volatility & risk, WHWK or AVTX?

Which has stronger valuation & earnings, WHWK or AVTX?

Do insiders & institutionals believe in WHWK or AVTX?

Does the media favor WHWK or AVTX?

Do analysts recommend WHWK or AVTX?

Is WHWK or AVTX more profitable?

Summary

How does Whitehawk Therapeutics compare to WAVE Life Sciences?

Is WHWK or WVE more profitable?

Do analysts prefer WHWK or WVE?

Do insiders and institutionals hold more shares of WHWK or WVE?

Which has stronger earnings & valuation, WHWK or WVE?

Does the media favor WHWK or WVE?

Which has more risk & volatility, WHWK or WVE?

Summary

How does Whitehawk Therapeutics compare to Sensei Biotherapeutics?

Which has better valuation & earnings, WHWK or FTH?

Does the media favor WHWK or FTH?

Do institutionals & insiders hold more shares of WHWK or FTH?

Do analysts rate WHWK or FTH?

Is WHWK or FTH more profitable?

Which has more risk and volatility, WHWK or FTH?

Summary

How does Whitehawk Therapeutics compare to Sana Biotechnology?

Does the media prefer SANA or WHWK?

Do analysts rate SANA or WHWK?

Do institutionals and insiders hold more shares of SANA or WHWK?

Which has more volatility and risk, SANA or WHWK?

Is SANA or WHWK more profitable?

Which has stronger valuation & earnings, SANA or WHWK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools